Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | intermediate filament protein | 0.0032 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0032 | 1 | 1 |
Schistosoma mansoni | lamin | 0.0032 | 1 | 1 |
Schistosoma mansoni | intermediate filament proteins | 0.0032 | 1 | 1 |
Schistosoma mansoni | lamin | 0.0032 | 1 | 1 |
Echinococcus granulosus | lamin | 0.0032 | 1 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0022 | 0.4151 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.9646 | 0.9646 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0022 | 0.4151 | 0.5 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0032 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0022 | 0.4151 | 0.5 |
Echinococcus granulosus | lamin dm0 | 0.0032 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0032 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0022 | 0.4151 | 0.5 |
Echinococcus multilocularis | lamin | 0.0032 | 1 | 1 |
Onchocerca volvulus | 0.0032 | 1 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 1 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0022 | 0.4151 | 0.4151 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.1026 | 0.1026 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0022 | 0.4151 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0022 | 0.4151 | 0.5 |
Onchocerca volvulus | 0.0032 | 1 | 0.5 | |
Echinococcus multilocularis | lamin dm0 | 0.0032 | 1 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0022 | 0.4151 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0022 | 0.4151 | 0.5 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0022 | 0.4151 | 0.4151 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0022 | 0.4151 | 0.4151 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0022 | 0.4151 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0022 | 0.4151 | 0.5 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0022 | 0.4151 | 0.3482 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0022 | 0.4151 | 0.5 |
Echinococcus multilocularis | musashi | 0.0032 | 1 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0022 | 0.4151 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0022 | 0.4151 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0022 | 0.4151 | 0.5 |
Toxoplasma gondii | exonuclease III APE | 0.0022 | 0.4151 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 10 mg kg-1 | Antiviral activity against Forest virus (SFV) | ChEMBL. | 2999405 |
ED50 (functional) | = 80 mg kg-1 | Effective dose administered subcutaneously againist Forest virus infected mice | ChEMBL. | 2999405 |
ED50 (functional) | > 400 mg kg-1 | Effective dose administered perorally againist Forest virus infected mice | ChEMBL. | 2999405 |
IFN (functional) | = 500 ml | The compound was evaluated for the serum interferon response from a single 800 mg/kg intraperitoneal administration in vesicular stomatitis virus on L292 cells; Range 500-1000 units/mL | ChEMBL. | 2999405 |
IFN (functional) | = 500 ml | The compound was evaluated for the serum interferon response from a single 800 mg/kg intraperitoneal administration in vesicular stomatitis virus on L292 cells; Range 500-1000 units/mL | ChEMBL. | 2999405 |
Protection index (functional) | = 0.25 | Protection index after intraperitoneal administration of the compound (25 mg/kg/day) against herpes simplex virus type-1 (HSV-1) infected mice [protection index=(control mortality-treated mortality)/control mortality] | ChEMBL. | 2999405 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.